

Request title: Metastatic castration resistant prostate cancer (mCRPR)

Date of Response: 15th September 2015

Further to your Freedom of Information request, the Trust has answered your questions in the order they appear in your request.

Request and reply

How many patients with metastatic castration resistant prostate cancer (mCRPC) have received enzalutamide in the last 6 weeks?

50 patients.

- Of these patients, how many have received a prior course of docetaxel in the last 12 months?

7 patients.

How many patients with metastatic castration resistant prostate cancer (mCRPC) have received abiraterone in the last 6 weeks?

40 patients.

- Of these patients, how many have received a prior course of docetaxel in the last 12 months?

4 patients.

How many patients with Breast Cancer have been treated with the following in the past 6 months?

-Trastuzumab	-	55 patients
-Lapatinib	-	2 patients
-Pertuzumab	-	8 patients
-Everolimus	-	4 patients
-Denosumab	-	0
-Dasatinib	-	0
-trastuzumab emtansine	-	6 patients

How many patients with Advanced [Stage 4] Melanoma have been treated with the following in the past 6 months ?

-Dabrafenib	-	0
-Ipilimumab	-	9 patients
-Trametenib	-	0
-Vemurafenib	-	3 patients
-Dacarbazine	-	0
-Paclitaxel	-	0
-Pembrolizumab	-	0
-Nivolumab	-	0
-Bevacizumab	-	0

